Most Read Articles
Elvira Manzano, 28 Jul 2020
The efficacy and cardiovascular (CV) safety of the SGLT2* inhibitor empagliflozin vs DPP-4** inhibitors and GLP-1*** receptor agonists in real-world patients were demonstrated in two interim analyses of the EMPRISE+ study presented at ADA 2020.
Roshini Claire Anthony, 14 Sep 2020

Patients hospitalized with mild-to-moderate COVID-19 who are on angiotensin-converting enzyme (ACE) inhibitors or angiotensin receptor blockers (ARBs) for hypertension should continue these medications, according to primary results of the BRACE CORONA trial presented at ESC 2020.

Tristan Manalac, 09 Jul 2020
Left ventricular assist devices (LVADs) trigger almost immediate favourable metabolic changes in both diabetics and nondiabetics, according to a recent study.
29 Mar 2020
Targeting a low-density lipoprotein cholesterol level <70 mg/dL following an ischaemic stroke of atherosclerotic origin helps to avoid one in four subsequent major vascular events without increasing the risk of intracranial haemorrhage over about 5 years of follow-up, according to data from the Treat Stroke to Target trial.

Blood transfusion tied to higher complication risk after autologous breast reconstruction

11 Oct 2019

Blood transfusion occurs with a striking frequency among autologous breast reconstruction patients and is associated with an increased risk of surgery-related complications, a recent study has found.

The study included 55,840 patients (mean age, 52±10 years) who had undergone autologous breast reconstruction surgery from 2012 to 2014 in the United States. The primary study outcomes were the overall rate of blood transfusion and the associated risk factors and outcomes.

Seven percent of all participants required blood transfusion. This rate was lowest in those who underwent latissimus dorsi myocutaneous flap procedures (3.3 percent) and highest in the free gluteal artery perforator flap patients (22 percent).

Patients who underwent blood transfusion also suffered from complications much more frequently (29.55 percent vs 8.48 percent; p<0.01) and stayed in the hospital for a significantly longer duration (6.6 vs 3.6 days; p<0.01). Death was also more common in these patients (0.51 percent vs 0.02 percent; p<0.01).

All other complications, such as urinary tract infection, acute respiratory failure, wound infections and dehiscence, flap failure, myocardial infarction, stroke, and pneumonia, among others, occurred significantly more frequently in those who required blood transfusions. The only exceptions were fat necrosis (p=0.89) and seroma (p=0.17).

Multivariate regression analysis found that chronic anaemia, congestive heart failure, free flap, chronic kidney disease, hypertension, chronic lung disease, diabetes mellitus and obesity were significant risk factors for the need for blood transfusion.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Cardiology - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Elvira Manzano, 28 Jul 2020
The efficacy and cardiovascular (CV) safety of the SGLT2* inhibitor empagliflozin vs DPP-4** inhibitors and GLP-1*** receptor agonists in real-world patients were demonstrated in two interim analyses of the EMPRISE+ study presented at ADA 2020.
Roshini Claire Anthony, 14 Sep 2020

Patients hospitalized with mild-to-moderate COVID-19 who are on angiotensin-converting enzyme (ACE) inhibitors or angiotensin receptor blockers (ARBs) for hypertension should continue these medications, according to primary results of the BRACE CORONA trial presented at ESC 2020.

Tristan Manalac, 09 Jul 2020
Left ventricular assist devices (LVADs) trigger almost immediate favourable metabolic changes in both diabetics and nondiabetics, according to a recent study.
29 Mar 2020
Targeting a low-density lipoprotein cholesterol level <70 mg/dL following an ischaemic stroke of atherosclerotic origin helps to avoid one in four subsequent major vascular events without increasing the risk of intracranial haemorrhage over about 5 years of follow-up, according to data from the Treat Stroke to Target trial.